Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-28T05:03:27.818Z Has data issue: false hasContentIssue false
  • English
  • Français

Chronic facial pain following injection of sodium tetradecyl sulphate into an intraparotid haemolymphangioma

Published online by Cambridge University Press:  12 July 2007

D P Crampsey ,
L Cochrane ,
D Roebuck  and
B E Hartley
D P Crampsey*
Affiliation:
Department of Paediatric Otolaryngology and Head and Neck Surgery, Great Ormond Street Hospital for Children NHS Trust, London, UK
L Cochrane
Affiliation:
Department of Paediatric Otolaryngology and Head and Neck Surgery, Great Ormond Street Hospital for Children NHS Trust, London, UK
D Roebuck
Affiliation:
Department of Interventional Radiology, Great Ormond Street Hospital for Children NHS Trust, London, UK
B E Hartley
Affiliation:
Department of Paediatric Otolaryngology and Head and Neck Surgery, Great Ormond Street Hospital for Children NHS Trust, London, UK
*
Address for correspondence: Mr David P Crampsey, Specialist Registrar in Otolaryngology, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, Scotland, UK. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

We report a rare case of chronic facial pain following sclerotherapy for intraparotid haemolymphangioma, thereby highlighting an important clinical consideration when advising this treatment option as an alternative to surgery in the head and neck.

Method:

Case report, with a review of relevant literature.

Results:

Sclerotherapy of lymphangiomata is well reported in the literature. Unusually, our young patient with an intraparotid haemolymphangioma experienced severe, chronic pain following intralesional injection of sodium tetradecyl sulphate, which required management by a specialist pain service. We discuss the technique of sclerotherapy for such lesions, and also discuss the potential side effects of two agents commonly used in our centre: OK 432 and sodium tetradecyl sulphate.

Conclusion:

Non-surgical treatments of lymphangiomata and venous vascular malformations are not without complication. Both patient and clinician should be aware of this, and of the other potential side effects of sclerotherapy, prior to its use in the head and neck.

Keywords

LymphangiomaSclerotherapyLymphatic Malformation
Type
Clinical Record
Information
The Journal of Laryngology & Otology , Volume 122 , Issue 9 , September 2008 , pp. 1002 - 1004
Copyright
Copyright © JLO (1984) Limited 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Sichel, JY, Udassin, R, Gozal, D, Koplewitz, BZ, Dano, I, Eliashar, R. OK-432 therapy for cervical lymphangioma. Laryngoscope 2004;114:1805–9CrossRefGoogle ScholarPubMed
2 Minkow, B, Laufer, D, Gutman, D. Treatment of oral hemangiomas with local sclerosing agents. Int J Oral Surg 1979;8:18–21CrossRefGoogle ScholarPubMed
3 Giguere, CM, Bauman, NM, Smith, RJ. New treatment options for lymphangioma in infants and children. Ann Otol Rhinol Laryngol 2002;111:1066–75CrossRefGoogle ScholarPubMed
4 Bloom, DC, Perkins, JA, Manning, SC. Management of lymphatic malformations. Curr Opin Otolaryngol Head Neck Surg 2004;12:500–4CrossRefGoogle ScholarPubMed
5 Kane, WJ, Morris, S, Jackson, IT, Woods, JE. Significant hemangiomas and vascular malformations of the head and neck: clinical management and treatment outcomes. Ann Plast Surg 1995;35:133–43CrossRefGoogle ScholarPubMed
6 Woods, JE. Extended use of sodium tetradecyl sulfate in treatment of hemangiomas and other related conditions. Plast Reconstr Surg 1987;79:542–9CrossRefGoogle ScholarPubMed
7 O'Donovan, JC, Donaldson, JS, Morello, FP, Pensler, JM, Vogelzang, RL, Bauer, B. Symptomatic hemangiomas and venous malformations in infants, children, and young adults: treatment with percutaneous injection of sodium tetradecyl sulfate. Am J Roentgenol 1997;169:723–9CrossRefGoogle Scholar
8 Stroncek, DF, Hutton, SW, Silvis, SE, Vercellotti, GM, Jacob, HS, Hammerschmidt, DE. Sodium morrhuate stimulates granulocytes and damages erythrocytes and endothelial cells: probable mechanism of an adverse reaction during sclerotherapy. J Lab Clin Med 1985;106:498–504Google ScholarPubMed
9 Fujino, A, Moriya, Y, Morikawa, Y, Hoshino, K, Watanabe, T, Shimojima, N et al. A role of cytokines in OK-432 injection therapy for cystic lymphangioma: an approach to the mechanism. J Pediatr Surg 2003;38:1806–9CrossRefGoogle ScholarPubMed
10 Sung, MW, Lee, DW, Kim, DY, Lee, SJ, Hwang, CH, Park, SW et al. Sclerotherapy with picibanil (OK-432) for congenital lymphatic malformation in the head and neck. Laryngoscope 2001;111:1430–3CrossRefGoogle ScholarPubMed
11 Giguere, CM, Bauman, NM, Sato, Y, Burke, DK, Greinwald, JH, Pransky, S et al. Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial. Arch Otolaryngol Head Neck Surg 2002;128:1137–44CrossRefGoogle ScholarPubMed